Bioequivalence Of Two Formulations Of Monteluka...

Trauma In Elderly People Attended By A Mobile E...

Downregulation Of Il-8, Ecp, And Total Ige In T...

0 votes
Downregulation Of Il-8, Ecp, And Total Ige In The Tears Of Patients With Atopic Keratoconjunctivitis Treated With Rebamipide Eyedrops
Author: Mayumi Ueta, Jun Shoji, Chie Sotozono And Shigeru Kinoshita
Publisher: Derivative Works
12 pages
One time payment: €0.00
Required subscription: Free
Type of publication: Article
Follow this publisher

Share this publication:


Rebamipide eyedrops are approved in Japan for the treatment of dry eye disease. Some patients with allergic conjunctival diseases also manifest dry eye. Earlier we reported that rebamipide suppressed polyI:C-induced inflammatory cytokines in human conjunctival epithelial cells. In the current study we examined the effect of rebamipide eyedrops on the level of interleukin-8 (IL-8), eosinophil cationic protein (ECP), and total IgE on the ocular surface.We prescribed rebamipide eyedrops to patients with atopic keratoconjunctivitis (AKC) who presented with dry eye (6 eyes in 4 AKC patients) and measured the IL-8, ECP, and total IgE levels in their tears before- and 2, and 4-6 weeks after the start of rebamipide treatment. To measure the IL-8 and total IgE levels in their tears we used BDTM CBA Flex sets; ECP measurements were with ELISA. The level of IL-8, ECP, and total IgE in the tears of AKC patients was reduced significantly 4-6 weeks after the start of rebamipide treatment. We also recorded subjective symptoms associated with AKC, e.g. itching, foreign body sensation, and eye mucus discharge, by using a patient questionnaire. Their subjective symptoms associated with AKC were also significantly ameliorated at 2 and 4-6 weeks.Our observations suggest that the anti-inflammatory effects of rebamipide eyedrops help to combat human ocular surface inflammation and that they may be a new effective therapy in patients with AKC.

About the publisher:

We are a publishing house devoted to reuse CC-BY licensed published materials.


Using CC-BY licenses:


  • Adapt — remix, transform, and build upon the material
  • for any purpose, even commercially.
  • The licensor cannot revoke these freedoms as long as you follow the license terms.


  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others
    from doing anything the license permits.


  • You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
  • No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

Select a payment method